Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
X-TROZINE L.A. vs ACTIDIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
X-TROZINE L. A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
Hypertension (extended-release formulation),Off-label: Management of opioid withdrawal symptoms
Allergic rhinitis,Allergic conjunctivitis,Urticaria,Angioedema
250 mg orally once daily. May be increased to 500 mg once daily if needed.
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min).
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Primarily hepatic via CYP3A4; metabolites include inactive glucuronides.
Hepatic via CYP450 isoenzymes (primarily CYP3A4 and CYP2D6); undergoes N-demethylation and N-oxidation.
Primarily renal (70-80% as unchanged drug), with 20-30% fecal via biliary excretion.
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
95-98% bound to albumin and alpha-1-acid glycoprotein.
Approximately 90% bound to plasma proteins, primarily albumin.
0.8-1.2 L/kg, indicating extensive tissue distribution.
2.5-4.0 L/kg, indicating extensive tissue distribution.
Oral: 40-60% (due to first-pass metabolism); IM: 80-90%.
Oral bioavailability is approximately 50-60% due to first-pass metabolism.
Cr Cl 30-89 m L/min: 250 mg every 48 hours. Cr Cl <30 m L/min: 250 mg every 72 hours. Hemodialysis: 250 mg post-dialysis three times weekly.
GFR 10-50 m L/min: 2.5 mg every 6-8 hours; GFR <10 m L/min: 2.5 mg every 8-12 hours.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 250 mg once daily. Child-Pugh C: use is not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Children ≥2 years: 5 mg/kg orally once daily, maximum 250 mg. Adolescents: 250 mg once daily.
Children 2-5 years: 1.25 mg orally every 4-6 hours (max 5 mg/day); Children 6-12 years: 1.25-2.5 mg every 4-6 hours (max 7.5 mg/day).
Initiate at 125 mg once daily; titrate cautiously. Monitor renal function and adjust per renal guidelines.
Initiate at 1.25 mg orally every 6-8 hours; maximum 5 mg per day due to increased risk of anticholinergic effects and renal impairment.
X-TROZINE L. A. carries a black box warning for severe hypotension and syncope, especially on initial dosing or dose escalation; risk of orthostatic hypotension is increased with concomitant use of diuretics or beta-blockers.
None
May cause bradycardia and heart block; caution in patients with pre-existing cardiac conduction abnormalities. Avoid abrupt discontinuation due to risk of rebound hypertension. Use with caution in patients with renal impairment (dose adjustment recommended). May cause drowsiness and impaired cognitive function.
May cause drowsiness and impair mental alertness,Avoid alcohol and other CNS depressants,Use with caution in patients with narrow-angle glaucoma, prostatic hypertrophy, or urinary retention,Elderly patients are more susceptible to anticholinergic effects
Hypersensitivity to piperazine derivatives; severe bradycardia or sick sinus syndrome without pacemaker; concurrent use of MAO inhibitors; history of hepatic encephalopathy.
Hypersensitivity to any component,Concurrent use with monoamine oxidase inhibitors
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and may increase drug levels, raising risk of side effects. Take with or without food; if GI upset occurs, take with a small meal.
No specific food interactions, but taking with food may reduce GI side effects. Alcohol should be strictly avoided due to additive CNS depression. Grapefruit juice is not documented to interact.
First trimester: Associated with increased risk of neural tube defects (NTDs) and oral clefts based on animal studies and limited human data; second and third trimester: Risk of fetal growth restriction and oligohydramnios due to potential effects on placental perfusion.
First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Not associated with major congenital malformations. However, anticholinergic effects may cause neonatal tachycardia, irritability, and withdrawal symptoms if used near term.
Excreted into breast milk; M/P ratio approximately 0.8. Avoid breastfeeding due to potential adverse effects on infant neurodevelopment and risk of hypotonia.
Excretion into breast milk likely but negligible amounts; no adverse effects reported in infants. M/P ratio not established. Considered compatible with breastfeeding; monitor for sedation or irritability in neonate.
Increased clearance due to expanded plasma volume and enhanced hepatic metabolism; dose may need to be increased by 30-50% in the second and third trimesters; monitor therapeutic drug levels.
No specific dose adjustments required in pregnancy; however, use lowest effective dose due to potential anticholinergic effects. Pharmacokinetics may be altered (increased volume of distribution), but no dose adjustment recommended.
X-TROZINE L. A. is a long-acting antihistamine used for allergic rhinitis and chronic urticaria. Its peak effect occurs 6-12 hours post-dose; avoid concurrent use with CNS depressants due to additive sedation. In elderly patients, reduce dose to prevent anticholinergic side effects like urinary retention and blurred vision. Monitor liver function in patients with hepatic impairment as metabolism is hepatic via CYP3A4.
ACTIDIL (triprolidine) is a first-generation antihistamine with sedative properties. Use cautiously in elderly due to risk of confusion, urinary retention, and falls. Avoid in patients with narrow-angle glaucoma, BPH, or asthma. Administer with food if GI upset occurs. Onset of action is 30-60 minutes; duration 4-6 hours.
Take exactly as prescribed, usually once daily; do not crush or chew the extended-release tablet.,May cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Avoid alcohol and other sedatives to prevent increased drowsiness.,Notify your doctor if you experience vision changes, difficulty urinating, or rapid heartbeat.,Store at room temperature away from moisture and heat.
Do not drive or operate heavy machinery until you know how this medication affects you; it can cause drowsiness.,Avoid alcohol and other CNS depressants, as they may increase sedation.,Take exactly as prescribed; do not exceed recommended dose.,If you miss a dose, skip it; do not double the next dose.,Notify your doctor if you experience blurred vision, difficulty urinating, or severe drowsiness.,Do not use for prolonged periods without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about X-TROZINE L.A. vs ACTIDIL, answered by our medical review team.
X-TROZINE L.A. is a Antihistamine that works by X-TROZINE L. A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.. ACTIDIL is a Antihistamine that works by H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between X-TROZINE L.A. and ACTIDIL depend on the specific clinical indication. These are both Antihistamine agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of X-TROZINE L.A. is: 250 mg orally once daily. May be increased to 500 mg once daily if needed.. The standard adult dose of ACTIDIL is: 2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between X-TROZINE L.A. and ACTIDIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. X-TROZINE L.A. is classified as Category C. First trimester: Associated with increased risk of neural tube defects (NTDs) and oral clefts based on animal studies and limited human data; second and third trimester: Risk of fe. ACTIDIL is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Not associated with major congenital malformations. However, anticholinergi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.